Institution
University of South Florida
Education•Tampa, Florida, United States•
About: University of South Florida is a education organization based out in Tampa, Florida, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 34231 authors who have published 72644 publications receiving 2538044 citations. The organization is also known as: USF.
Topics: Population, Poison control, Cancer, Health care, Mental health
Papers published on a yearly basis
Papers
More filters
TL;DR: The authors presented a review of the book "Varieties of Capitalism: The Institutional Foundations of Comparative Advantage, edited by Peter Hall and David Soskice" with the same authors.
Abstract: The article presents a review of the book “Varieties of Capitalism: The Institutional Foundations of Comparative Advantage,” edited by Peter Hall and David Soskice.
689 citations
Fox Chase Cancer Center1, Johns Hopkins University2, University of Utah3, Roswell Park Cancer Institute4, Dana Corporation5, Stanford University6, University of Michigan7, University of Texas MD Anderson Cancer Center8, Duke University9, Memorial Sloan Kettering Cancer Center10, Northwestern University11, University of South Florida12, University of Nebraska–Lincoln13, City of Hope National Medical Center14
TL;DR: Overview All cancers develop as a result of mutations in certain genes, such as those involved in the regulation of cell growth and/or DNA repair, but not all of these mutations are inherited from a parent.
Abstract: Overview All cancers develop as a result of mutations in certain genes, such as those involved in the regulation of cell growth and/or DNA repair,1,2 but not all of these mutations are inherited from a parent. For example, sporadic mutations can occur in somatic/ tumor cells only, and de novo mutations can occur for the first time in a germ cell (i.e., egg or sperm) or in the fertilized egg itself during early embryogenThe NCCN
686 citations
Tufts University1, San Diego State University2, Kaiser Permanente3, Anschutz Medical Campus4, Pennsylvania State University5, Georgia Institute of Technology6, University of Hawaii7, University of South Florida8, Kraft Foods9, University of North Carolina at Chapel Hill10, Indiana University11, University of Nevada, Reno12
TL;DR: This research highlights the need to understand more fully the rationale behind the rapid decline in physical activity in middle-aged people over a longer period of time.
Abstract: Sarah L. Booth, Ph.D., Vitamin K Laboratory, Jean Mayer USDAHuman Nutrition Research Center on Aging at Tufts University, Boston, MA; James F. Sallis, Ph.D., F.A.C.S.M., Department ofPsychology, San Diego State University, San Diego, CA; Cheryl Ritenbaugh, Ph.D., M.P.H., Kaiser Permanente Center for Health Research, Portland, O R James 0. Hill, Ph.D., Center for Human Nutrition, University of Colorado Health Sciences Center, Denver, CO; Leann L. Birch, Ph.D., Department ofHuman Development and Family Studies, Pennsylvania State University, University Park, PA; Lawrence D. Frank, Ph.D., College OfArchitecture, Georgia Institute of Technology, Atlanta, GA; Karen Glanz, Ph.D., M.P.H., Cancer Research Center of Hawaii, University of Hawaii, Honolulu, HI; David A. Himmelgreen, Ph.D., Department ofAnthropology, University of South Florida, Tampa, FL; Michael Mudd, Corporate Affairs, Kraft Foods, Inc., Northfield, IL; Barry M. Popkin, Ph.D., Department ofNutrition, Carolina Population Center, University of North Carolina, Chapel Hill, NC; Karyl A. Rickard, Ph.D., R.D., C.S.P., F.A.D.A., Nutrition and Dietetics Program, School ofAllied Health Sciences, Indiana University School of Medicine, Indianapolis, IN; Sachiko St. Jeor, Ph.D., R.D., Nutrition Education and Research Program, University of Nevada School of Medicine, Reno, W, Nicholas P. Hays, M.S., Energy Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA.
685 citations
Harvard University1, University of South Florida2, University of Washington3, University of British Columbia4, University of Ottawa5, Boston Children's Hospital6, Christiana Care Health System7, University of Minnesota8, University of Vermont9, Washington University in St. Louis10, Food and Drug Administration11, Wayne State University12, University of Pennsylvania13, Englewood Hospital and Medical Center14, Yale University15, Canadian Blood Services16, University of Massachusetts Medical School17, University of Texas Southwestern Medical Center18, Johns Hopkins University19, Children's National Medical Center20
TL;DR: These guidelines were designed to provide pragmatic recommendations, based on the best available published evidence, about when platelet transfusion may be appropriate in adult patients, and provide advice for adult patients who are candidates for platelets transfusion.
Abstract: Platelet transfusions are administered to prevent or treat bleeding in patients with quantitative or qualitative platelet disorders The AABB (formerly, the American Association of Blood Banks) dev
684 citations
University of Washington1, Harvard University2, University of South Florida3, Fox Chase Cancer Center4, Sheba Medical Center5, Yale University6, Seoul National University7, Johns Hopkins University8, University of North Carolina at Chapel Hill9, Tel Aviv Sourasky Medical Center10, National Taiwan University11, Yonsei University12, Merck & Co.13, University of Chicago14
TL;DR: Fixed-dose pembrolizumab 200 mg administered once every 3 weeks was well tolerated and yielded a clinically meaningful ORR with evidence of durable responses, which supports further development of this regimen in patients with advanced HNSCC.
Abstract: Purpose Treatment with pembrolizumab, an anti-programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) -positive recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-012 trial. Results from the expansion cohort, in which patients with HNSCC, irrespective of biomarker status, received a fixed dose of pembrolizumab at a less frequent dosing schedule, are reported. Patients and Methods Patients with R/M HNSCC, irrespective of PD-L1 or human papillomavirus status, received pembrolizumab 200 mg intravenously once every 3 weeks. Imaging was performed every 8 weeks. Primary end points were overall response rate (ORR) per central imaging vendor (Response Evaluation Criteria in Solid Tumors v1.1) and safety. Secondary end points included progression-free survival, overall survival, and association of response and PD-L1 expression. Patients who received one or more doses of pembrolizumab were included in analyses. Results Of 132 patients enrolled, median age was 60 years (range, 25 to 84 years), 83% were male, and 57% received two or more lines of therapy for R/M disease. ORR was 18% (95% CI, 12 to 26) by central imaging vendor and 20% (95% CI, 13 to 28) by investigator review. Median duration of response was not reached (range, ≥ 2 to ≥ 11 months). Six-month progression-free survival and overall survival rates were 23% and 59%, respectively. By using tumor and immune cells, a statistically significant increase in ORR was observed for PD-L1-positive versus -negative patients (22% v 4%; P = .021). Treatment-related adverse events of any grade and grade ≥ 3 events occurred in 62% and 9% of patients, respectively. Conclusion Fixed-dose pembrolizumab 200 mg administered once every 3 weeks was well tolerated and yielded a clinically meaningful ORR with evidence of durable responses, which supports further development of this regimen in patients with advanced HNSCC.
678 citations
Authors
Showing all 34549 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| David J. Hunter | 213 | 1836 | 207050 |
| Aaron R. Folsom | 181 | 1118 | 134044 |
| John Hardy | 177 | 1178 | 171694 |
| David Cella | 156 | 1258 | 106402 |
| Arul M. Chinnaiyan | 154 | 723 | 109538 |
| Andrew D. Hamilton | 151 | 1334 | 105439 |
| Charles B. Nemeroff | 149 | 979 | 90426 |
| C. Ronald Kahn | 144 | 525 | 79809 |
| Alexander Belyaev | 142 | 1895 | 100796 |
| Tasuku Honjo | 141 | 712 | 88428 |
| Weihong Tan | 140 | 892 | 67151 |
| Alison Goate | 136 | 721 | 85846 |
| Peter Kraft | 135 | 821 | 82116 |
| Xiaodong Wang | 135 | 1573 | 117552 |
| Lars Klareskog | 131 | 697 | 63281 |